Sonoma Pharmaceuticals, Inc. Balance Sheet
SNOA|15 years of annual SEC 10-K data (FY2011-FY2026)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | - | $5.4M | $3.1M | $3.8M | $7.4M | $3.7M | $3.7M | $10.1M | $17.5M | $7.5M | $6.1M | $5.5M | $7.9M | $3.4M | $4.4M |
| Accounts Receivable | - | $2.2M | $2.9M | $2.6M | $2.4M | $2.8M | $4.1M | $3.5M | $1.5M | $2.1M | $2.3M | $1.5M | $1.8M | $1.7M | $2.2M |
| Inventory | - | $2.9M | $2.7M | $2.9M | $2.7M | $2.5M | $2.2M | $3.4M | $2.9M | $2.2M | $1.6M | $1.4M | $1.1M | $992.0K | $953.0K |
| Current Assets | - | $12.6M | $12.5M | $13.8M | $16.4M | $13.0M | $12.4M | $12.5M | $16.3M | $22.6M | $12.9M | $9.6M | $9.5M | $11.5M | $7.0M |
| PP&E (Net) | - | $225.0K | $365.0K | $488.0K | $320.0K | $360.0K | $365.0K | $727.0K | $1.1M | $1.2M | $850.0K | $795.0K | $971.0K | $800.0K | $806.0K |
| Total Assets | - | $13.7M | $14.7M | $16.2M | $18.8M | $15.0M | $14.6M | $14.4M | $19.2M | $25.5M | $13.8M | $15.0M | $20.8M | $12.6M | $7.8M |
| Current Liabilities | - | $4.1M | $3.7M | $3.7M | $5.8M | $4.1M | $4.9M | $3.6M | $3.3M | $3.3M | $3.6M | $2.6M | $7.6M | $5.1M | $4.7M |
| Total Debt | - | - | - | - | $0 | $1.3M | $0 | $12.0K | $32.0K | $45.0K | - | - | $4.0K | $676.0K | $1.8M |
| Shareholders' Equity | - | $6.1M | $8.0M | $8.7M | $5.4M | $5.6M | $10.5M | $15.3M | $21.4M | $10.1M | $12.1M | $12.1M | $4.1M | -$868.0K | $1.7M |